Impact of the COVID-19 pandemic on lung transplant patients and on a cohort of patients with rare lung disease: A single-center study.

COVID-19 Lifestyle factors Lung transplantation Protective measures Rare lung disease

Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 12 11 2023
revised: 19 01 2024
accepted: 01 03 2024
medline: 25 4 2024
pubmed: 25 4 2024
entrez: 24 4 2024
Statut: aheadofprint

Résumé

Due to the COVID-19 pandemic, France underwent several lockdown periods during 2020. Our aim was to evaluate its clinical and social impact on lung transplant (LT) patients treated at Strasbourg University Hospital, by comparing three periods: first lockdown (T1: March-May 2020), end of the first lockdown (T2: May-October 2020), and second lockdown (T3: November-December 2020) and the incidence of COVID-19 infections. A cohort of patients with rare lung disease (RLD) was also studied during T2. We used clinical and paraclinical data collected during routine follow-up. A questionnaire was submitted to each patient at each period to assess their lifestyle, adherence to protective measures against COVID-19, contacts with their family and friends, and contagion risk. The incidence of new COVID-19 cases was also assessed. Overall, 283 LT and 57 RLD patients were included. We observed only eight COVID-19 cases over the three periods (n = 4 during T1, n = 0 during T2, and n = 4 during T3) in LT patients, with 37.5 % of patients hospitalized, no ICU transfers, and 100 % favorable outcomes. No case of COVID-19 was diagnosed in the RLD cohort. When comparing the three periods in the LT group, fewer patients limited their out-of-home activities during T2 (p < 0.0001). The frequency of these activities increased after the first lockdown, for the purchase of basic necessities (p < 0.0001), and professional activity continued (p = 0.008). We observed a significant increase in unscheduled medical consultations and in the prescription of anti-infective treatments during the end of the lockdown (p = 0.0002 and p = 0.005, respectively). Adherence to lockdown and to protective measures was high in both groups of patients. COVID-19 incidence remained low in both groups and there were significant lifestyle evolutions in LT patients and in those with RLD between first and second lockdown.

Identifiants

pubmed: 38657294
pii: S2590-0412(24)00016-3
doi: 10.1016/j.resmer.2024.101100
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101100

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Moustapha Hussein (M)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Floriane Gallais (F)

Laboratory of Virology, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Tristan Dégot (T)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Sandrine Hirschi (S)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Justine Leroux (J)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Marianne Riou (M)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Julien Stauder (J)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Pierre-Emmanuel Falcoz (PE)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Anne Olland (A)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.

Romain Kessler (R)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France; INSERM UMR 1260 - Regenerative nanomedicine, Université de Strasbourg, Strasbourg, France.

Benjamin Renaud-Picard (B)

Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France; INSERM UMR 1260 - Regenerative nanomedicine, Université de Strasbourg, Strasbourg, France. Electronic address: benjamin.renaudpicard@chru-strasbourg.fr.

Classifications MeSH